Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://alfredi530ofv7.wikiconversation.com/user